Details About Generic Salt ::  Hetastar

Main Medicine Class:: Plasma expander   

(HET-uh-starch)

Hespan

Class: Plasma expander

 

Drugs Class ::

 Action Produces expansion of plasma volume. Does not have oxygen-carrying capacity or contain plasma protein, so it is not blood or plasma substitute.

Indications for Drugs ::

 Indications Adjunct therapy for plasma volume expansion in shock due to hemorrhage, burns, surgery, sepsis, or other trauma; adjunct in leukapheresis to improve harvesting and increase yield of granulocytes.

Drug Dose ::

 Route/Dosage

Plasma Volume Expansion

ADULTS: IV 500 to 1000 ml/day; dosage does not usually exceed 1500 ml/day.

Leukapheresis

ADULTS: IV 250 to 700 ml.

Contraindication ::

 Contraindications Severe bleeding disorders; severe cardiac failure; renal failure with oliguria or anuria.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: No data available. Special risk patients: Due to possibility of circulatory overload, take special care when administering to patients with renal impairment, at risk of pulmonary edema, or with CHF. Hypersensitivity: May cause anaphylactoid reactions.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CNS: Headache. DERM: Itching. EENT: Submaxillary and parotid glandular enlargement. GI: Vomiting. OTHER: Anaphylactoid reactions (eg, periorbital edema, urticaria, wheezing, mild temperature elevation); chills; mild influenza-like symptoms; muscle pain; peripheral edema of lower extremities.

Drug Mode of Action ::  

 Action Produces expansion of plasma volume. Does not have oxygen-carrying capacity or contain plasma protein, so it is not blood or plasma substitute.

Drug Interactions ::

 Interactions None well documented.

Drug Assesment ::

 Assessment/Interventions

• Obtain complete history, including drug history and any known allergies.
• Assess for bleeding disorders and severe cardiac failure with oliguria or anuria.
• Take baseline vital signs and hematologic parameters before administration of drug.
• Check vital signs q 5 min for first 30 min following administration.
• Monitor urinary output. If output does not increase, report to health care provider.
• Monitor CVP during infusion to assess for circulatory overload (elevated CVP, rales/crackles, shortness of breath during and after administration).
• Report prolonged PT, PTT, bleeding and clotting times, decreased Hct, decreased plasma proteins to health care provider.
• Report anaphylactoid reactions (eg, periorbital edema, urticaria, wheezing, fever), chills, muscle pain, peripheral edema to health care provider.
• During leukapheresis, monitor CBC, differential WBC count, Hgb, Hct, PT, and PTT.

Drug Storage/Management ::

 Administration/Storage

• Administer by IV infusion only.
• Store at room temperature.
• Do not use if solution is turbid deep brown or if crystalline precipitate forms.

Drug Notes ::

 Patient/Family Education

• Instruct patient to report these symptoms to health care provider: Itching, dyspnea, chills, myalgia, headache, vomiting and glandular enlargement.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.